New method maps the dopamine system in Parkinson's patients

February 14, 2018, Karolinska Institutet
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

With the aid of a PET camera, researchers from Karolinska Institutet in Sweden have developed a new method for investigating the dopamine system in the brains of patients suffering from Parkinson's disease. The method measures levels of a protein called dopamine transporter and could lead to improved diagnosis of Parkinson's disease and the development of new treatments. The study is published in the scientific journal Movement Disorders.

Dopamine is a substance produced in the brain and is responsible for controlling our movements. The cells that produce are located in an area known as the brainstem, from where dopamine is then secreted into the basal ganglia, an area of the brain that plays an important function in regulating our movements.

In Parkinson's disease, dopamine cells degenerate and their loss is responsible for the motor symptoms that characterise the disorder, such as shaking, slowness of movement and difficulty in walking.

Using a special brain imaging technique known as Positron Emission Tomography (PET), a group of researchers at Karolinska Institutet have measured the levels of the protein DAT that regulates the levels of dopamine in the brain. DAT functions as a biomarker for dopamine cells and is present on the surface of the dopamine cells in the cell bodies, on the and on the nerve endings. By measuring where DAT is found, researchers have been able to map the presence of dopamine cells.

The study was based on 20 patients suffering from mild Parkinsonism and an equal number of healthy individuals. The results showed significantly lower amounts of DAT in in the Parkinson's patients than those not suffering from the disease. However, the amount of DAT remained relatively intact in cell bodies and nerve fibres.

"These results suggest that in the early stages of the disease dopamine are still viable and that, given the correct treatment, it should be possible to restore their function," says Andrea Varrone, senior lecturer in nuclear medicine at Karolinska Institutet's Department of Clinical Neuroscience who led the study.

"The method we have developed is likely to be able to assist in the diagnosis of Parkinson's disease at an earlier stage and predict the development of the disease. DAT can also be used as a biomarker in clinical trials of new medicines and treatment strategies," he continues.

Future studies will examine patients with more advanced Parkinson's, in order to gain a greater understanding of the links between DAT and clinical variables such as and the various stages of the disease.

Explore further: Conversion of brain cells offers hope for Parkinson's patients

More information: Patrik Fazio et al. Nigrostriatal dopamine transporter availability in early Parkinson's disease, Movement Disorders (2018). DOI: 10.1002/mds.27316

Related Stories

Conversion of brain cells offers hope for Parkinson's patients

April 11, 2017
Researchers at Karolinska Institutet have made significant progress in the search for new treatments for Parkinson's disease. By manipulating the gene expression of non-neuronal cells in the brain, they were able to produce ...

Restless sleep may be an early sign of Parkinson's disease

December 6, 2017
Restless sleep could be a sign of a disorder associated with diseases of the brain. Researchers from Aarhus University conducted a case-control study on the condition of the dopamine-producing nerve cells in the brain and ...

Scientific discovery may change treatment of Parkinson's disease

March 22, 2017
When monitoring Parkinson's disease, SPECT imaging of the brain is used for acquiring information on the dopamine activity. A new study conducted in Turku, Finland, shows that the dopamine activity observed in SPECT imaging ...

Impulsivity in Parkinson's disease

October 30, 2017
Dopamine medications are effective in treating the motor symptoms of Parkinson's disease (PD), but dopamine agonists can trigger impulsive-compulsive behaviors (ICBs), such as compulsive gambling, eating or shopping, in a ...

Neurotrophic factor GDNF is an important regulator of dopamine neurons in the brain

February 16, 2017
New research results are expanding our understanding of the physiological role of the glial cell line-derived neurotrophic factor GDNF in the function of the brain's dopamine systems. In an article recently published in the ...

Mechanisms behind sensory deficits in Parkinson's disease

May 18, 2017
Although Parkinson's disease is often associated with motor symptoms such as stiffness, poor balance and trembling, the first symptoms are often sensory and include a reduced sense of touch and smell. In a study on mice, ...

Recommended for you

New Parkinson's disease drug target revealed through study of fatty acids

December 4, 2018
The human brain is rich in lipids. Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the ...

A toxin that travels from stomach to brain may trigger Parkinsonism

December 4, 2018
Combining low doses of a toxic herbicide with sugar-binding proteins called lectins may trigger Parkinsonism—symptoms typical of Parkinson's disease like body tremors and slowing of body motions—after the toxin travels ...

Experimental cancer drug shows promise for Parkinson's

December 3, 2018
The study, funded by Parkinson's UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson's. This happens when the drug interacts with a protein inside brain ...

Parkinson's therapy creates new brain circuits for motor function, study finds

November 28, 2018
Scientists have uncovered that an emerging gene therapy for Parkinson's disease creates new circuits in the brain associated with improved motor movement. These findings, published today in Science Translational Medicine ...

The puzzle of a mutated gene lurking behind many Parkinson's cases

November 15, 2018
Genetic mutations affecting a single gene play an outsized role in Parkinson's disease. The mutations are generally responsible for the mass die-off of a set of dopamine-secreting, or dopaminergic, nerve cells in the brain ...

Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson's disease

November 14, 2018
A defining feature of Parkinson's disease is the clumps of alpha-synuclein protein that accumulate in the brain's motor control area, destroying dopamine-producing neurons. Natural processes can't clear these clusters, known ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.